Document is current
Any future updates will be listed below
-
Authors
Coles, Theresa https://orcid.org/0000-0003-2941-8999
Plyler, Kate
Hernandez, Alexy
Fillipo, Rebecca
Henke, Debra M.
Arizmendi, Cara
Goodwin, C. Rory
LeBlanc, Thomas W.
Lagoo-Deenadayalan, Sandhya
Reeve, Bryce B.
Weinfurt, Kevin P.
-
Funding
Funding for this research was provided by:
U.S. Food and Drug Administration (75F40120C00069)
- License Information
-
More Information
Article History
Accepted: 13 November 2024
First Online: 4 December 2024
Declarations
:
: TC has research funding from Merck and Pfizer; a prior consulting agreement with Regenxbio; and received a speaking honorarium from ISPOR. CA was a fellow at Duke (2021–2023) funded by AstraZeneca and is now an employee at AstraZeneca (2023-present). CRG is a consultant for Stryker and Medtronic. BBR had a consulting role with Novartis. TWL has received honoraria for consulting/advisory boards from AbbVie, Agilix, Agios/Servier, Apellis, Astellas, AstraZeneca, BlueNote, BMS/Celgene, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer; speaking related honoraria from AbbVie, Agios, Astellas, BMS/Celgene, Incyte, and Rigel; equity interest in Dosentrx (stock options in a privately-held company); royalties from UpToDate; research funding from the AbbVie, American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, GSK, Jazz Pharmaceuticals, and Seattle Genetics. TWL is a Scholar in Clinical Research of the Leukemia & Lymphoma Society. BBR has received honoraria for participating in a meeting with Novartis. All other authors have no disclosures.
